Gland Pharma receives approval for phytonadione injection emulsion
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Eugia Steriles receives EIR from USFDA for new injectable facility
Subscribe To Our Newsletter & Stay Updated